
AstraZeneca quietly exits neuroscience
AstraZeneca on Tuesday confirmed it has closed down its neuroscience research group to direct resources toward more “high value” projects. On an earnings call with investors, Sharon Barr, AstraZeneca’s head of biopharmaceuticals research and development, …